MedDataX Logo

SYMBICORT® in the Treatment of COPD

NCT ID: NCT00564499

Last Updated: 2011-01-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Study Classification

OBSERVATIONAL

Study Start Date

2006-03-31

Study Completion Date

2007-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Symbicort in Chronic Obstruktive Pulmonary Disease

NCT00612976

Pulmonary Disease, Chronic Obstructive
COMPLETED

Symbicort in Chronic Obstructive Pulmonary Disease

NCT00611520

Chronic Obstructive Pulmonary Disease
COMPLETED

Symbicort Turbuhaler 30/60 Special Clinical Experience Investigation for Long-term Use for Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT01713075

Chronic Obstructive Pulmonary Disease
COMPLETED

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935

COPD Patients
COMPLETED PHASE3

Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)

NCT01253473

Pulmonary Disease, Chronic Obstructive
COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COPD

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CROSSOVER

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria

* patients who recently quit smoking (\<3months)
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

E Louis, PR

Role: PRINCIPAL_INVESTIGATOR

Université Libre de Liège

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SRP-RB-COPD-2005/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Comparative Effectiveness of Symbicort vs. Advair Among COPD Patients
NCT01921127 COMPLETED
Evaluation of Onset of Effect in Patients With Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Symbicort® Compared to Seretide®
NCT00542880 COMPLETED PHASE4
Study of Bosentan in the Treatment of Stable Severe Chronic Obstructive Pulmonary Disease Patients
NCT02093195 UNKNOWN PHASE2
A Comparison of SYMBICORT® pMDI With Formoterol Turbuhaler® in Subjects With COPD
NCT00419744 COMPLETED PHASE3
A Safety and Efficacy Study of Symbicort Turbuhaler Compared With Standard Chronic Obstructive Pulmonary Disease (COPD) Treatment in Japan
NCT01070784 COMPLETED PHASE3
Phase IV O2 Consumption Study in COPD Patients.
NCT02533505 COMPLETED PHASE4
Efficacy and Safety Study of Symbicort® Turbuhaler® Versus Oxis® Turbuhaler® in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01069289 COMPLETED PHASE3
Evaluation of Efficacy on Exercise Tolerance of Symbicort (Budesonide/Formoterol) Compared to Placebo and Oxis in Patients With Severe COPD
NCT00489853 COMPLETED PHASE4
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and 2 x 80/4.5 μg Bid With Formoterol Turbuhaler® 2 x 4.5 μg Bid and Placebo in Patients With COPD
NCT00206167 COMPLETED PHASE3
Evaluation of Symbicort® Turbuhaler® (Budesonide/Formoterol) in Chronic Obstructive Pulmonary Disease (COPD)
NCT00837629 COMPLETED
Efficacy and Safety Study of Symbicort Turbuhaler in Chinese Patients With COPD
NCT00421122 COMPLETED PHASE3
Effect of Symbicort on HAT and HDAC in Sputum Macrophages of COPD
NCT00291408 WITHDRAWN PHASE4
Adherence Study in COPD Patients
NCT02864342 COMPLETED PHASE4
Study to Assess the Safety and Efficacy of PT010, PT003, and PT009 in Japanese Subjects With COPD Compared With Symbicort® Turbohaler®
NCT03262012 COMPLETED PHASE3
Changes in Cardiac Function in COPD Patients After Administration of Budesonide/Formoterol (Symbicort®) Versus Placebo
NCT01760304 TERMINATED PHASE4
The Study Will Evaluate the Effect of AZD8683 in Patients With Chronic Obstructive Pulmonary Disease (COPD)
NCT01205269 COMPLETED PHASE2
A Randomized, Double-Blind, Parallel-Group, 24-Week, Chronic-Dosing, Multi-Center Study to Assess the Efficacy and Safety of PT010, PT003, and PT009 Compared With Symbicort® Turbuhaler® (Kronos)
NCT02497001 COMPLETED PHASE3
Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD
NCT02766608 COMPLETED PHASE3
Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT01415518 COMPLETED PHASE4
Effect of Symbicort ® on GR in Sputum in COPD
NCT01787097 COMPLETED PHASE4
Effects of Symbicort on the Ventilatory Kinematics
NCT01712854 TERMINATED PHASE4
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD Patients
NCT00206154 COMPLETED PHASE3
Efficacy of AZD3199 in Chronic Obstructive Pulmonary Disease (COPD) Patients
NCT00929708 COMPLETED PHASE2
Efficacy of Inhaling Bronchodilator Medications in Chronic Obstructive Pulmonary Disease
NCT01391559 COMPLETED NA
A Study to Investigate the Differential Effects of Inhaled Symbicort and Advair on Lung Microbiota
NCT02833480 UNKNOWN PHASE2